Rapid Micro Biosystems Q4 revenue $8.2M (+30% YoY); gross margin turns positive; announces MilliporeSigma deal

RAPID MICRO BIOSYSTEMS, INC.

2024-FY EPS reported -$1.08 revenue$28,051,000

Q4 2024 revenue $8.2M (up 30% vs $6.3M in Q4 2023); product revenue $5.2M (+27%), service revenue $3.0M (+35%).
Q4 gross margin 12% (improved from negative 3% in Q4 2023); net loss $9.7M ($0.22 loss per share) vs $11.2M loss.
FY 2024 revenue $28.1M (+25%); net loss $46.9M ($1.08 per share) improved from $52.5M loss in 2023.
FY 2025 guidance: total revenue at least $32.0M with 21-25 system placements expected.
Entered global Distribution & Collaboration Agreement with MilliporeSigma for co-exclusive rights to sell Growth Direct systems and consumables.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.